Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the motor neurons, leading to loss of strength in the extremities, problems eating and speaking, and problems with respiration. ALS is the most common of the motor neuron diseases (MND). There is no known cure for ALS and the mean survival period is 3–5 years from the disease onset (Tiryaki and Horak Reference Tiryaki and Horak2014). Younger age at symptom onset as well as duration of symptoms correlate to longer survival (Kollewe et al. Reference Kollewe, Mauss and Krampfl2008). Besides the symptoms related to loss of motor neuron function, patients with MND, such as ALS, are at risk of increased prevalence of pain (Tiryaki and Horak Reference Tiryaki and Horak2014), lower quality of life (QOL), and depression (Heidari et al. Reference Heidari, Nadali and Parouhan2021).
The fatal outcome and the rapid progression of the disease result in caregivers focusing on palliative treatment to help patients with ALS cope with the disabling disease and provide the best possible quality of life (Karam et al. Reference Karam, Paganoni and Joyce2016). Recently, individual quality of life (IQOL) was reported as good (Jakobsson Larsson et al. Reference Jakobsson Larsson, Ozanne and Nordin2017), and no association with pain was found in cross-sectional findings of patients with MND, possibly explained by patients’ ability to cope with their situation (Åkerblom et al. Reference Åkerblom, Zetterberg and Larsson2021).
Individual quality of life differs from health-related quality of life (HRQOL), by allowing the individual to select areas of their own choice of importance for their HRQOL (Neudert et al. Reference Neudert, Wasner and Borasio2004). However, when measuring HRQOL, the result may be different. The HRQOL in patients with MND is influenced by several factors; moreover, associations with progression of the disease (Prell et al. Reference Prell, Gaur and Stubendorff2019), pain, and depression symptoms (Sandstedt et al. Reference Sandstedt, Johansson and Ytterberg2016) are reported.
In a review on the pooled prevalence of pain in people with ALS, as many as 60% had pain (Hurwitz et al. Reference Hurwitz, Radakovic and Boyce2021); furthermore, when studied prospectively, pain intensity did not change over time (Wigand et al. Reference Wigand, Schlichte and Schreiber2021). Studies on the associations between HRQOL and pain in MND point to conflicting results; two studies reported no correlation (Ganzini et al. Reference Ganzini, Johnston and Hoffman1999; Lopes et al. Reference Lopes, Galhardoni and Silva2018). Nevertheless, Pagnini et al. (Reference Pagnini, Lunetta and Banfi2012) found that higher pain intensity was associated with worse HRQOL. The results were similar in another study until adjustment for depression, which highlights the need to take depression into account when discussing HRQOL (Pizzimenti et al. Reference Pizzimenti, Aragona and Onesti2013). A recent review established that depression is prevalent in 34% of the people with ALS (Heidari et al. Reference Heidari, Nadali and Parouhan2021) but, in a recent longitudinal study, Wigand et al. (Reference Wigand, Schlichte and Schreiber2021) found no conclusive evidence of the association between pain and depressive symptoms. Given the prevalence of both pain and depression in MND, and the inconclusive evidence from previous studies concerning associations with QOL, further studies on this association are warranted (Heidari et al. Reference Heidari, Nadali and Parouhan2021).
Therefore, the aim of this study was to describe the reported levels of pain over time during disease progression in individual patients and for a total sample of people with MND. Another aim was to examine the association between pain, disease severity, HRQOL, and depression.
Materials and methods
The study was a prospective cohort study, including data collection on five occasions over a period of 2 years. Patients were included in the study from September 2015 and the last follow-up was conducted in September 2019. The study was performed in agreement with the Declaration of Helsinki and approved by the Regional Ethics Committee in Uppsala, Sweden (Approval No. 2015/293). The patients confirmed participation by signing an informed consent form.
Settings and participants
Data were collected from four multi-disciplinary teams in Sweden, specialized in MND care. Fifteen health professionals with an extensive experience of treating patients with MND were involved in the data collection at the four sites.
Patients were considered eligible if over 18 years of age, had a MND diagnosis according to El Escorial Criteria (Ludolph et al. Reference Ludolph, Drory and Hardiman2015), and scheduled for routine visits at any of the four multidisciplinary MND teams. Patients were thus included at different states of their MND. Patients having a severe impact on cognitive function, difficulties understanding or expressing themselves in Swedish, and patients with another neurological disease affecting the symptoms of MND were excluded. In addition, patients with Kennedy’s disease were excluded due to the sensory impact of the disease possibly affecting the perception of pain (Querin et al. Reference Querin, Sorarù and Pradat2017).
Outcomes and measures
Pain was measured with the Short Form of Brief Pain Inventory (BPI-SF) (Cleeland and Ryan Reference Cleeland and Ryan1994). The BPI-SF measures the presence of pain, pain severity, body regions affected, treatments for pain, and pain interference in different activities (Cleeland and Ryan Reference Cleeland and Ryan1994). In the present study, two subscales were used: presence of pain and pain severity during the past 24 h. Presence of pain was indicated with “yes/no.” Severity of pain was rated on four 11-point numeric rating scales (NRS) for worst, least, and average pain intensity during the past 24 h, and for current pain. The anchors were labeled: 0 = “no pain” and 10 = “worst imaginable pain” (Cleeland Reference Cleeland2009). An average of 0–3 is considered no or mild, 4–6 as moderate, and 7–10 as severe pain (Hoffman et al. Reference Hoffman, Sadosky and Dukes2010). The measure is considered to be valid for several painful conditions (Celik et al. Reference Celik, Yalcinkaya and Atamaz2017; de Andres Ares et al. Reference de Andres Ares, Cruces Prado and Canos Verdecho2015; Naegeli et al. Reference Naegeli, Tomaszewski and Al Sawah2015) and has been widely used to evaluate pain in neuromuscular disorders, including ALS (Chiò et al. Reference Chiò, Canosa and Gallo2012; Hanisch et al. Reference Hanisch, Skudlarek and Berndt2015; Hoffman et al. Reference Hoffman, Jensen and Abresch2005; Stephens et al. Reference Stephens, Lehman and Raheja2015; Wallace et al. Reference Wallace, Ellis and Burman2014). The internal consistency is high with Cronbach’s α 0.84–0.93 in participants with non-cancer pain, systemic lupus erythematosus, and musculoskeletal pain (Celik et al. Reference Celik, Yalcinkaya and Atamaz2017; de Andres Ares et al. Reference de Andres Ares, Cruces Prado and Canos Verdecho2015; Naegeli et al. Reference Naegeli, Tomaszewski and Al Sawah2015). In the present study, the Cronbach’s α was 0.93.
Depression was assessed using the ALS-Depression-Inventory (ADI-12). Patients were asked to state how much they agreed with each statement on a 4-point Likert-scale with regard to the last 2 weeks. Scores range from 0 (best possible) to 48 (worst possible) with scores >23 identifying all patients with any depressive disorder and the corresponding specificity is of 60%. The internal consistency is high (Cronbach’s α = 0.91) and the ADI-12 is correlated to the Beck Depression-Inventory (Pearson correlation coefficient = 0.81) (Hammer et al. Reference Hammer, Häcker and Hautzinger2008). The Cronbach’s α was 0.93 in the present study.
Disability progression was measured using the Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised Version (ALSFRS-R) (Cedarbaum et al. Reference Cedarbaum, Stambler and Malta1999). This functional rating scale includes four subscales measuring bulbar, fine motor, gross motor, and respiratory function. Each subscale includes three items ranging from 0 (totally lost) to 4 (normal function), resulting in a total score of 12 for each of the subscales. Lower scores indicate a higher level of dysfunction (Cedarbaum et al. Reference Cedarbaum, Stambler and Malta1999). The internal consistency was previously reported as high, Cronbach’s α 0.73 (Cedarbaum et al. Reference Cedarbaum, Stambler and Malta1999), and the corresponding number was 0.86 in the present study. The construct validity of the total score correlates with HRQOL measured with the Sickness Impact Profile, r s = −0.72 and with pulmonary function (forced vital capacity %) r s = 0.41 (Cedarbaum et al. Reference Cedarbaum, Stambler and Malta1999).
Health-Related Quality of Life was assessed using the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5). The patients were asked to state how much difficulties they had experienced during the last 2 weeks on a 5-point Likert-scale; total scores range from 0 to 20 (20 indicating the best health status). The five items include: physical function in the lower extremity, physical function in the upper extremities, eating and drinking, communication, and psychological well-being. The ALSAQ-5 was reported with a valid measure of the original 40 items ALSAQ version (Jenkinson and Fitzpatrick Reference Jenkinson and Fitzpatrick2001). The Cronbach’s α was 0.66 in the present study.
Demographic data
Demographic data were collected during the visits. It included gender, age, family situation, level of education, occupational status, time since first perceived disease symptoms, self-reported comorbidity, and experience of chronic pain before the onset of MND.
Procedure
An information letter was sent to the patients ahead of their scheduled visit to the MND team, and oral information about the study was provided during the visit. After the patients had given their informed consent, data were collected during the visit to the clinic. To reduce the length of the clinical visit, the participants completed the BPI-SF (Cleeland and Ryan Reference Cleeland and Ryan1994) at home.
Data management and analysis
Descriptive statistic was presented in number and percentage for categorical data, mean, and standard deviation for continuous data, and the median was presented with minimum (min) and maximum (max) values for ordinal data.
For evaluation of time lived with MND symptoms, sub-cohorts were generated based on time since the first perceived symptoms. The participants were divided into three sub-cohorts: 0–24 months, 24.1–60 months, and >60 months from symptom onset.
When comparing two groups, Mann–Whitney’s U-test was used to test for significance. When comparing more than two groups, Kruskal–Wallis test was performed to test if at least one group differed from the other. To test the significance of associations, a Spearman’s rank correlation coefficient was calculated. The number included in each analysis is presented in Tables 1–4. The level of significance was set at p ≤ 0.05. All statistics were performed in R version 4.1.0 (Vienna, Austria).
Participants’ characteristics at baseline
a ALS = amyotrophic lateral sclerosis, with both upper and lower motor neuron signs.
b MND = motor neuron disease with lower motor neuron signs and symptoms.
c BPI-SF = Brief Pain Inventory – Short Form.
d ALSAQ-5 = Amyotrophic Lateral Sclerosis Assessment Questionnaire.
e ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised.
f ADI-12 = Amyotrophic Lateral Sclerosis (ALS)-Depression-Inventory.
Results
Participants’ characteristics
In total, 68 participants were included in the study and 46 participants (67.6%) did not participate in the last assessment; the drop-outs were due to participants being too ill or having passed away. The majority of the participants are men; most lived with a partner (79.5%) and were either retired or received sickness benefits full-time (72%). The detailed characteristics of the participants are presented in Table 1.
Individual variation of pain over time
The participants reported 4 (min 0 and max 10) in the median level of worst pain during the last 24 h at baseline. To illustrate the variation of self-reported pain throughout the study period, Figure 1 shows the worst pain scores during the last 24 h for each individual and as an average for each of the three sub-cohorts. No clear patterns in the course of pain were seen throughout the study. In some individuals, pain intensity appeared rather stable, whereas in others, the pain fluctuated between high and low levels.
Line plots for each individual for the variable BPI worst pain during the last 24 h. The last three-line plots show the average for the three sub-cohorts.
Association and prognostic value of pain for future depression, function, or HRQOL
The prognostic values of pain on future depression, function, or HRQOL; associations between baseline values of BPI average pain and BPI worst pain during the last 24 h; and depression, function, and HRQOL are presented in Table 2.
Spearman rank correlations between baseline pain (BPI average and worst pain during the last 24 h) and depression (ADI-12), function (ALSFRS-R) and quality of life ALSAQ at the five visits
a BPI-SF = Brief Pain Inventory Short Form.
b ADI-12 = Amyotrophic Lateral Sclerosis (ALS)-Depression-Inventory.
c ADI-12 was only assessed at the 1st and 5th visit.
d ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised.
e ALSAQ-5 = Amyotrophic Lateral Sclerosis Assessment Questionnaire.
* and bold values are significant at the 5% level).
At the baseline visit, higher levels of pain during the last 24 h were associated with higher depression scores (ADI-12), a poorer quality of life (ALSAQ-5), and lower reporting of fine and gross motor skills (ALSFRS-R). The baseline level of pain, however, did not predict the future values of depression, function, or HRQOL.
Pain intensity
The comparisons of quality of life (ALSAQ-5), time since the first symptom of disease, function (ALSFRS-R), and depression (ADI-12) in patients experiencing lower and higher levels of pain are reported in Table 3. Age, time lived with symptoms, and the total score on quality of life did not differ between the participants reporting lower or higher levels of pain. However, individuals reporting average pain >3, to a larger degree, experienced hopelessness toward the future and reported a higher depression score compared with participants reporting average pain <3.
Comparison between individuals with pain less than 3 versus pain 3 or more using Mann–Whitney’s U-test
a BPI-SF = Brief Pain Inventory – Short Form (pain severity rated from 0 = “no pain” and 10 = “worst imaginable pain”).
b ALSAQ-5 = Amyotrophic Lateral Sclerosis Assessment Questionnaire (scores range from 0 to 20 (20 indicating the best health status)).
c ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised. Each subscale includes three items ranging from 0 (totally lost) to 4 (normal function), making a total score of 12 for each of the subscales. Lower scores indicate a higher level of dysfunction.
d ADI-12 = Amyotrophic Lateral Sclerosis (ALS)-Depression-Inventory; ADI-12 (scores range from 0 (best possible) to 48 (worst possible)).
* and bold values are significant at the 5% level.
Time lived with motor neuron disease symptoms
The time lived with MND symptoms ahead of study inclusion is illustrated in Figure 2. Participants were assessed on five occasions at the most during the study. The proportion of patients with ALS in sub-groups 1–3 were 68%, 65%, and 33%, respectively. There were large variations in the number of total follow-up visits, based on the time since the first symptoms. Nearly, half (48.1%) of the first sub-cohort (0–24 months) died during the study period compared with 27.6% in the second sub-cohort (24.1–60 months) and 8.3% in the third sub-cohort, which also had the longest time (>60 months) from the first symptoms to study inclusion.
Follow-up visits and time from first symptom, standardized to first symptom. The individuals were categorized into three sub-cohorts, based on their time from first symptom at the first visit. The three sub-cohorts are: 0–24: between 0 and 24 months from first symptom at first visit; 24.1–60: between 24.1 and 60 months from first symptom at first visit; >60: over 60 months from first symptom at first visit. A black dot symbolizes death after visit.
Time in study
Participants who participated in their 5th visit were younger, had lived for a longer time since they first experienced symptoms, and reported a lower score in the ALSQ-5, indicating a higher quality of life. Participants attending the 5th visit reported lower on the ADI-12, indicating a lower presence of depression on a group level. There was no difference between the groups in pain or disease severity, as reported in the ALSFRS-R (see Table 4).
Comparison of baseline values for the 26 individuals who came to the 5th follow-up visit against the 42 individuals who did not have a 5th visit. Mann–Whitney’s U-test is used as the significance test
a BPI-SF = Brief Pain Inventory Short Form (pain severity rated from 0 = “no pain” and 10 = “worst imaginable pain”).
b ALSAQ-5 = Amyotrophic Lateral Sclerosis Assessment Questionnaire (scores range from 0 to 20 (20 indicating the best health status)).
c ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised. Each subscale includes three items ranging from 0 (totally lost) to 4 (normal function), making a total score of 12 for each of the subscales. Lower scores indicate a higher level of dysfunction.
d ADI-12 = Amyotrophic Lateral Sclerosis (ALS)-Depression-Inventory; ADI-12 (scores range from 0 (best possible) to 48 (worst possible)).
* and bold values are significant at the 5% level.
Discussion
To the best of our knowledge, this is one of a few prospective studies following a cohort of patients with MND over a longer time. Data were collected on up to five occasions during a period of 2 years, providing a unique opportunity for identification of how pain varies over time and the associations between pain and HRQOL, function, and depression.
At baseline, pain was present in 68.3% of the study participants, which is at the higher end of previously reported data on prevalence (Hurwitz et al. Reference Hurwitz, Radakovic and Boyce2021). The intensity of worst pain experienced during the last 24 h was at a moderate level (median 4), and a mild level was reported regarding average pain (median 3) (Hoffman et al. Reference Hoffman, Sadosky and Dukes2010). These findings are comparable to those reported in a review by Hurwitz et al. (Reference Hurwitz, Radakovic and Boyce2021).
The three sub-cohorts, based on time since the first symptoms, were relatively stable regarding the mean levels of worst pain during the last 24 h throughout the study. This is in accordance with the longitudinal findings by Wigand et al. (Reference Wigand, Schlichte and Schreiber2021). Interestingly, when observing the individuals in our study, a large variance was found, i.e., some individuals reported no pain (NRS = 0) during one visit and high levels of pain (NRS = 8) on another visit or vice versa. These findings corroborate the results of our previous qualitative study, where we found patients experienced that pain fluctuated over time and that it was very hard to predict, even on a day-to-day basis (Åkerblom et al. Reference Åkerblom, Jakobsson Larsson and Zetterberg2020). Taken together, these studies underline the importance of having tailored assessments and treatment, as the level of pain varies both within and between individuals (Åkerblom et al. Reference Åkerblom, Jakobsson Larsson and Zetterberg2020; Chiò et al. Reference Chiò, Canosa and Gallo2012).
In contrast to one study (Ganzini et al. Reference Ganzini, Johnston and Hoffman1999), but in line with Pagnini et al. (Reference Pagnini, Lunetta and Banfi2012), the pain reported in this cohort was associated with poor HRQOL at baseline. The association remained similar during all visits; however, it was only significant at the 1st and 3rd visit for worst pain during the last 24 h. Moreover, higher levels of pain were significantly associated with more symptoms of depression at baseline, but the association was not significant at the follow-up. Both HRQOL and symptoms of depression were moderately correlated with pain at baseline, but the strength of the association weakened and lost significance at the later assessments. This may be an expression of patients adapting to their life situation, referred to as a response shift (Sprangers and Schwartz Reference Sprangers and Schwartz1999) due to a redefinition of internal standards and values. The loss of significance may also be due to the lower number of participants at the later assessments, which makes significant correlations less likely. Hence, our findings highlight that pain is not a predictor of future depression, function, and HRQOL on a group level; nonetheless, the results should be interpreted with caution due to the decreased power over time and the high within-individual variation.
In the present study, 32.3% of the patients died during the study period. In the sub-cohort of patients having had symptoms from 0 to 24 months before inclusion, the mortality was higher (48.1%). This may be an expression of a larger proportion of patients with a rapid disease progression. Time from the first symptoms was not associated with the average intensity of pain, indicating that the duration of the disease is not a predictor of pain intensity.
Methodological considerations
From disease onset, the mean survival period is short, and high mortality would be expected in prospective studies with MND patients. Analysis of those taking part in the 5th and last visit in the study adds information on the characteristics of individuals surviving the study period and being able to participate in the whole study. Those who participated in the 5th visit were younger, had lived longer with disease symptoms, had better HRQOL, and significantly fewer depression symptoms at baseline. Participants taking part in the 5th visit may experience a slower progression of the disease, which indicates that these individuals belong to another phenotype of MND (Grad et al. Reference Grad, Rouleau and Ravits2017).
MND are rare in the general population (Barceló et al. Reference Barceló, Povedano and Vázquez-Costa2021) and, as expected, inclusion of a large number of participants was a challenge. We included participants from multi-disciplinary MND teams in specialized care from different geographic locations to increase the number of participants and the generalizability to patients with MND in Sweden. This approach allowed us to collect baseline data from a reasonable number of patients.
The fast progression of the disease makes it challenging to prospectively follow patients with MND. During a 2-year follow-up period, the number of participants may be expected to decrease due to increased disease severity or death. However, to study the disease over time, a prospective design is needed, which is a major strength of this study. The prospective design allowed for analyses of variation of pain for each individual throughout the five assessments over the two-year study period, which gave valuable data on within-individual variation. Moreover, analysis of the prognostic value of pain intensity was also possible. The high number of drop-outs was an expected limitation, and the lack of significant associations at the follow-up may in part be due to the decreased power throughout the study.
The information on time since first MND symptoms was based on self-report and might therefore be subjected to recall bias. Nevertheless, this approach was deemed to be an appropriate indication of disease onset.
The instruments used to measure depression, disability progression, and HRQOL were all disease specific questionnaires. This is a considerable strength compared to generic instruments, as MND specific instruments are adjusted to the non-curative and fast progressive nature of the disease (Jenkinson et al. Reference Jenkinson, Fitzpatrick and Brennan1999). The internal consistency was good for ADI-12, ALSFRS-R, and BPI. The internal consistency of ALSAQ-5 was lower in this study, which may hamper the reliability of the instrument; thus, caution should be taken when interpreting the results.
Conclusion and clinical implications
This longitudinal study, following patients with MND on several occasions over two years, found great within-individual variation of pain intensity.
Pain intensity was associated with depression and HRQOL cross-sectionally, but it did not appear to have a strong prognostic value for future depression, function, or HRQOL.
In accordance with these and our previous qualitative findings, patients with MND should be offered frequent assessments of pain and depressive symptoms in a person-centered care approach, allowing for individualization of adequate pain management.
Funding
This work was supported by grants from Ulla-Carin foundation and trough a regional agreement between Uppsala County Council and Uppsala University Hospital (ALF).
Competing interests
None.
Open access
